

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, NEW ZEELAND, SOUTH AFRICA, HONG KONG OR SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL



PRESS RELEASE

Moberg Pharma announces prospectus regarding admission to trading of new shares

STOCKHOLM, December 16th, 2016.

The prospectus regarding the admission to trading of newly issued shares in Moberg Pharma AB (publ) ("Moberg Pharma") is now available on the company's website, www.mobergpharma.se, and in the company's offices, at Gustavslundsvägen 42, 167 51 Bromma. Documents incorporated by reference in the prospectus are also available in accordance with the above.

The prospectus has been prepared due to the admission to trading of the 1,414,586 new shares in Moberg Pharma, that were issued in connection with the directed share issue to a limited group of Swedish and international institutional qualified investors, which was announced on December 7th, 2016. The newly issued shares are expected to be admitted to trading on or about December 20th, 2016.

For more information, please contact:

Peter Wolpert, CEO, telephone: +4670 - 735 71 35, e-mail: peter.wolpert@mobergpharma.se

Anna Ljung, CFO, telephone: +4670 - 766 60 30, e-mail: anna.ljung@mobergpharma.se

About this information

The information was submitted for publication, through the contact person set out above, at 10.00 p.m. (CET) on December 16th, 2016.

About Moberg Pharma, www.mobergpharma.com

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company's portfolio includes the OTC brands Kerasal[®], Kerasal Nail[®], Balmex[®], NewSkin[®], Domeboro[®], Fiber Choice[®] and PediaCare[®] (under divestment). Kerasal Nail[®] (Emtrix[®] or Nalox[™] in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focuses on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the Company's shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX:MOB).

Disclaimer/Notice

This communication is not an offer of securities for sale in the United States or any other jurisdiction. Any securities referred to in this communication may not be offered or sold in the United States or any other jurisdiction absent registration under applicable securities laws or an exemption from registration.